Dr. Jhaveri on T-DM1 in the Neoadjuvant Setting

Komal L. Jhaveri, MD
Published: Friday, Feb 21, 2014

Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.

Jhaveri says T-DM1 is already being looked at in the neoadjuvant setting. In one trial, researchers are looking to incorporate T-DM1 into the upfront setting and will evaluate two arms: docetaxel, carboplatin, and trastuzumab (TCH) versus T-DM1 plus pertuzumab. In the KATHERINE trial, patients who did not achieve pathologic complete response will be randomized to T-DM1 or trastuzumab in the adjuvant setting.

T-DM1 is being used in different ways, Jhaveri says, and it’s utility in the neoadjuvant setting remains to be seen.
Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.

Jhaveri says T-DM1 is already being looked at in the neoadjuvant setting. In one trial, researchers are looking to incorporate T-DM1 into the upfront setting and will evaluate two arms: docetaxel, carboplatin, and trastuzumab (TCH) versus T-DM1 plus pertuzumab. In the KATHERINE trial, patients who did not achieve pathologic complete response will be randomized to T-DM1 or trastuzumab in the adjuvant setting.

T-DM1 is being used in different ways, Jhaveri says, and it’s utility in the neoadjuvant setting remains to be seen.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x